Railway Pension Investments Ltd Sells 10,800 Shares of IDEXX Laboratories, Inc. $IDXX

Railway Pension Investments Ltd reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 154,330 shares of the company’s stock after selling 10,800 shares during the period. Railway Pension Investments Ltd owned approximately 0.19% of IDEXX Laboratories worth $82,773,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Lido Advisors LLC increased its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Lido Advisors LLC now owns 1,976 shares of the company’s stock worth $1,060,000 after purchasing an additional 22 shares during the last quarter. Schroder Investment Management Group grew its holdings in IDEXX Laboratories by 295.1% during the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after buying an additional 235,863 shares in the last quarter. Mackenzie Financial Corp increased its stake in IDEXX Laboratories by 0.8% in the 2nd quarter. Mackenzie Financial Corp now owns 149,522 shares of the company’s stock worth $80,195,000 after acquiring an additional 1,199 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its stake in IDEXX Laboratories by 42.7% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 23,335 shares of the company’s stock worth $12,515,000 after acquiring an additional 6,978 shares during the last quarter. Finally, F m Investments LLC raised its holdings in shares of IDEXX Laboratories by 0.5% during the 2nd quarter. F m Investments LLC now owns 27,311 shares of the company’s stock worth $14,648,000 after acquiring an additional 133 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.4%

IDXX opened at $753.05 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock’s 50 day moving average price is $666.95 and its 200-day moving average price is $605.72. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock has a market cap of $60.13 billion, a price-to-earnings ratio of 62.70, a P/E/G ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. BTIG Research upped their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of IDEXX Laboratories in a report on Tuesday. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.